Literature DB >> 10795697

Comparative study of Tc-99m MIBI and TI-201 SPECT in predicting chemotherapeutic response in non-small-cell lung cancer.

Y Nishiyama1, Y Yamamoto, K Satoh, M Ohkawa, K Kameyama, E Hayashi, J Fujita, M Tanabe.   

Abstract

PURPOSE: Tc-99m MIBI can be excluded from cytosol against its concentration gradient as a suitable transport substrate by P-glycoprotein. Tc-99m MIBI has also been shown to be more effective than TI-201 chloride for evaluating the response to chemotherapy in patients with small-cell lung cancer. The relation between Tc-99m MIBI accumulation by the tumor and its response to chemotherapy were evaluated in patients with non-small-cell lung cancer (NSCLC) and compared with the same parameters achieved using TI-201 chloride.
METHODS: Thirty-eight patients with NSCLC were examined before chemotherapy was begun. They were classified according to the results of a follow-up computed tomogram into two groups: responders were patients in whom there was a > or =50% decrease and nonresponders were patients in whom there was a <50% decrease in the sum of the product of the maximum perpendicular diameters of all measurable lesions. All patients underwent dual-isotope imaging with TI-201 chloride and Tc-99m MIBI just before chemotherapy. Regions of interest were placed over the tumor uptake (T) and contralateral normal lung tissue (N) areas on one coronal view with a clearly defined lesion, and the T:N ratio and retention index were calculated.
RESULTS: The delayed T:N ratio and retention index for Tc-99m MIBI in the responder group were significantly greater (P<0.05) than those in the nonresponder group. There was no significant correlation between the T:N ratio and retention index and tumor response using TI-201 chloride.
CONCLUSION: Tc-99m MIBI SPECT may be more effective than TI-201 chloride SPECT for evaluating the response to chemotherapy in patients with NSCLC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10795697     DOI: 10.1097/00003072-200005000-00010

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  7 in total

Review 1.  ABC transporters: unvalidated therapeutic targets in cancer and the CNS.

Authors:  Robert W Robey; Paul R Massey; Laleh Amiri-Kordestani; Susan E Bates
Journal:  Anticancer Agents Med Chem       Date:  2010-10-01       Impact factor: 2.505

2.  To use MIBI or not to use MIBI? That is the question when assessing tumour cells.

Authors:  Jean-Luc Moretti; Nathalie Hauet; Meltem Caglar; Olivier Rebillard; Zeynep Burak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07       Impact factor: 9.236

Review 3.  Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.

Authors:  Laleh Amiri-Kordestani; Agnes Basseville; Karen Kurdziel; Antonio Tito Fojo; Susan E Bates
Journal:  Drug Resist Updat       Date:  2012-03-29       Impact factor: 18.500

4.  A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.

Authors:  Ronan J Kelly; Deborah Draper; Clara C Chen; Robert W Robey; William D Figg; Richard L Piekarz; Xiaohong Chen; Erin R Gardner; Frank M Balis; Aradhana M Venkatesan; Seth M Steinberg; Tito Fojo; Susan E Bates
Journal:  Clin Cancer Res       Date:  2010-11-16       Impact factor: 12.531

Review 5.  99mTc-MIBI in the evaluation of breast cancer biology.

Authors:  Silvana Del Vecchio; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-23       Impact factor: 9.236

6.  Predicting early chemotherapy response with technetium-99m methoxyisobutylisonitrile SPECT/CT in advanced non-small cell lung cancer.

Authors:  Tzu-I J Yang; Tjeerd S Aukema; Harm van Tinteren; Sjaak Burgers; Renato Valdés Olmos; Marcel Verheij
Journal:  Mol Imaging Biol       Date:  2009-09-12       Impact factor: 3.488

Review 7.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.